Maximilian Stahl, MD

I conduct clinical and translational research in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

In my clinical research, I evaluate outcomes achieved with novel therapeutic approaches for AML, MDS and MPNs with a focus on identifying molecular predictors of these outcomes. For example, I have examined the effectiveness of hypomethylating agents (HMA) in AML (Blood Advances 2018) and MDS (Cancer 2017 and Blood 2018), immunosuppressive therapy in MDS (Blood Advances 2018 and Haematologica 2020), interferon therapy in MPNs (Leukemia 2020 and Clin Lymphoma, Myeloma, Leukemia 2020) and leukapheresis in hyperleukocytosis (Leukemia 2020 and Transfusion 2020). I have also studied molecular predictors of response to the bcl-2 inhibitor venetoclax in AML (Blood Advances 2021).
In addition, I have in interest in translational research with the goal to bring basic scientific discoveries from the laboratory bench to the clinic in order to benefit leukemia patients. Towards this goal, I conduct early phase clinical trials testing novel treatment approaches for patients with AML, MDS and MPNs.
Lastly, I have a strong interest in medical education and consider teaching fellows, residents and medical students an important part of my daily work. I served as chief medical resident during my residency training at Yale and as a chief fellow during my fellowship training at Memorial Sloan Kettering Cancer Center.